Lung cancer biomarkers inform treatment options

Our view is that patients in NZ should be tested for the following biomarkers at the time of diagnosis (and informed of the results irrespective of the reimbursement status of treatment options); ALK, EGFR, KRAS, RET, MET, ROS1, BRAF, HER2, NTRK1 And PD-L1. We too consider these diagnostic procedures should be part of all DHB’s standard laboratory contract with Labtests (or other provider).

Click to view infographic –